Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Neurological Disease Treatment Market: By Drug Type: Antiepileptic, Antipsychotic, Antidepressant, Others; By Disease Type; By Route of Administration; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments

Global Neurological Disease Treatment Market Outlook

The global market for neurological disease treatment is expected to grow at a CAGR of about 5.7% in the forecast period of 2022-2027, owing to the increasing prevalence of neurological disorders.

 

North America to be a Significant Regional Market for Neurological Disease Treatment

The global market for neurological disease treatment is expected to be dominated by North America. One of the key reasons for the growth of the North American market is the increasing prevalence of neurological diseases across the region. According to the Alzheimer's Association, around 6 million people in the United States are currently living with Alzheimer's. The number of people suffering from this condition is projected to reach 13 million by 2050. An estimated 6.5 million Americans aged 65 and above will be living with Alzheimer's in 2022. Also, growing healthcare spending and the availability of a matured and well-established nature of healthcare infrastructure are expected to propel the market growth in North America. Government agencies, including the United States Food and Drug Administration, which manages central nervous system treatment regulatory guidelines, are expected to support the market's growth. Further, the launch of new treatments for treating these diseases, such as Huntington's disease, may drive the growth of the global neurological disease treatment market in the region. For instance, in December 2021, Novartis received approval from the US Food and Drug Administration (FDA) for Fast Track designation for branaplam (LMI070) for the treatment of Huntington's disease (HD).

 

Market Segmentations

Medically, neurological diseases are issues that affect the brain and the nerves found throughout the human body, including the spinal cord. Medicines may be administered via drug pumps, deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, and spinal surgery may be used to treat nervous system diseases or disorders.

Based on drug type, the neurological disease treatment market is divided into:

  • Antiepileptic
  • Antipsychotic
  • Antidepressant
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Others

The various types of disease studied in the market are:

  • Alzheimer’s Disease
  • Cerebrovascular Disease
  • Parkinson’s Disease
  • Epilepsy
  • Multiple Sclerosis
  • Others

By route of administration, the market can be divided into:

  • Oral
  • Parenteral
  • Others

The end-uses of the neurological disease treatment market are:

  • Hospitals
  • Speciality Clinics
  • Homecare
  • Others

The regional markets for neurological disease treatment can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

 

Increasing Incidence of Neurological Diseases Propelling the Market Growth

The rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease, among others, are fuelling the expansion of the neurological disease treatment market. According to the National Library of Medicine, the predicted global population of people with multiple sclerosis reached 2.8 million in 2020. This rise is expected to have a significant impact on market growth in the coming years. The rising prevalence of neurological disorders and rising diagnosis rates in both developed and developing countries have resulted in a large patient pool requiring treatment. This is further assisted by non-profit organisations, healthcare institutions, and market participants focusing on raising awareness of these disorders through campaigns. These factors, together with the development of a new generation of antipsychotic medications by global and domestic market participants, are expected to fuel the market's growth potential. In addition, the rising research and development activities to find remedies for such ailments are driving the global market growth.

 

Key Players in the Global Market for Neurological Disease Treatment

The report gives a detailed analysis of the following key players in the global neurological disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • AbbVie Inc.
  • Abbott Laboratories
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Neurological Disease Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Neurological Disease Treatment Historical Market (2017-2021) 
    8.3    Global Neurological Disease Treatment Market Forecast (2022-2027)
    8.4    Global Neurological Disease Treatment Market by Drug Type
        8.4.1    Antiepileptic
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
        8.4.2    Antipsychotic
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
        8.4.3    Antidepressant
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
        8.4.4    Cholinesterase Inhibitors
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
        8.4.5    NMDA Receptor Antagonists
            8.4.5.1    Market Share
            8.4.5.2    Historical Trend (2017-2021)
            8.4.5.3    Forecast Trend (2022-2027)
        8.4.6    Others
    8.5    Global Neurological Disease Treatment Market by Disease Type
        8.5.1    Alzheimer’s Disease
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Cerebrovascular Disease
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Parkinson’s Disease
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Epilepsy
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Multiple Sclerosis
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2017-2021)
            8.5.5.3    Forecast Trend (2022-2027)
        8.5.6    Others
    8.6    Global Neurological Disease Treatment Market by Route of Administration
        8.6.1    Oral
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Parenteral
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
        8.6.3    Others
    8.7    Global Neurological Disease Treatment Market by End Use
        8.7.1    Hospitals
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2017-2021)
            8.7.1.3    Forecast Trend (2022-2027)
        8.7.2    Speciality Clinics
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2017-2021)
            8.7.2.3    Forecast Trend (2022-2027)
        8.7.3    Homecare
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2017-2021)
            8.7.3.3    Forecast Trend (2022-2027)
        8.7.4    Others
    8.8    Global Neurological Disease Treatment Market by Region
        8.8.1    Market Share
            8.8.1.1    North America
            8.8.1.2    Europe
            8.8.1.3    Asia Pacific
            8.8.1.4    Latin America
            8.8.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    AbbVie Inc.
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Abbott Laboratories
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    Merck & Co., Inc.
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    F. Hoffmann-La Roche Ltd
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Gilead Sciences, Inc.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Others
12    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Neurological Disease Treatment Market: Key Industry Highlights, 2017 and 2027
2.    Global Neurological Disease Treatment Historical Market: Breakup by Treatment Type (USD Million), 2017-2021
3.    Global Neurological Disease Treatment Market Forecast: Breakup by Treatment Type (USD Million), 2022-2027
4.    Global Neurological Disease Treatment Historical Market: Breakup by Disease Type (USD Million), 2017-2021
5.    Global Neurological Disease Treatment Market Forecast: Breakup by Disease Type (USD Million), 2022-2027
6.    Global Neurological Disease Treatment Historical Market: Breakup by End Use (USD Million), 2017-2021
7.    Global Neurological Disease Treatment Market Forecast: Breakup by End Use (USD Million), 2022-2027
8.    Global Neurological Disease Treatment Historical Market: Breakup by Region (USD Million), 2017-2021
9.    Global Neurological Disease Treatment Market Forecast: Breakup by Region (USD Million), 2022-2027
10.    North America Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
11.    North America Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Europe Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Europe Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Asia Pacific Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Asia Pacific Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Latin America Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Latin America Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Middle East and Africa Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
19.    Middle East and Africa Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
20.    Global Neurological Disease Treatment Market Structure.

Key Questions Answered in the Report

The market is projected to grow at a CAGR of 5.7% between 2022 and 2027.

The major drivers of the market include the growing healthcare spending, availability of a matured and well-established nature of healthcare infrastructure, launch of new treatments for treating these diseases, rising awareness of these disorders, and rising research and development activities.

The rapidly increasing prevalence and incidences of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease, and the rising diagnosis rates in both developed and developing countries are the key industry trends propelling the growth of the market.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

Based on drug type, the market is divided into antiepileptic, antipsychotic, antidepressant, cholinesterase inhibitors, and NMDA receptor antagonists, among others.

The various types of disease studied in the market are Alzheimer’s disease, Cerebrovascular disease, Parkinson’s disease, epilepsy, and multiple sclerosis, among others.

Based on route of administration, the market includes oral and parenteral, among others.

The end-uses of the market are hospitals, speciality clinics, and homecare, among others.

The major players in the industry are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and Gilead Sciences, Inc., among others.

Analyst Review

The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease in the historical period. Aided by the growing healthcare spending and rising diagnosis rates in both developed and developing countries, the market is expected to grow at a CAGR of 5.7% in the forecast period of 2022-2027.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug type, the market is divided into antiepileptic, antipsychotic, antidepressant, cholinesterase inhibitors, and NMDA receptor antagonists, among others. The various types of disease studied in the market are Alzheimer’s disease, Cerebrovascular disease, Parkinson’s disease, epilepsy, and multiple sclerosis, among others. Based on route of administration, the market includes oral and parenteral, among others. The end-uses of the market are hospitals, speciality clinics, and homecare, among others. The major regional markets for neurological disease treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and Gilead Sciences, Inc., among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports





NEWSLETTER